Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

San Fran’s I/O dar­ling Nek­tar Ther­a­peu­tics $NK­TR is hand­ing off ac­cess to its pop­u­lar can­cer can­di­date NK­TR-214 to see how the ther­a­py fairs when paired with Syn­dax’s strug­gling drug enti­no­s­tat.

The duo inked a col­lab­o­ra­tion and li­cens­ing deal that gives Syn­dax $SNDX the right to run a com­bo study test­ing the drugs against metasta­t­ic melanoma in pa­tients who have pre­vi­ous­ly pro­gressed when on an an­ti-PD-1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER